EMERYVILLE, Calif.--(BUSINESS WIRE)--NovaBay® Pharmaceuticals, Inc. (NYSE MKT: NBY), a biopharmaceutical company commercializing and developing topical non-antibiotic antimicrobial products for the global eye care market, announces that it has rescheduled the date to report third quarter financial results and hold an investment community conference call to Thursday, November 19, from the previously announced date of Monday, November 16.
| DATE: | Thursday, November 19, 2015 | ||||
| TIME: | 8:30 a.m. Eastern time / 5:30 a.m. Pacific time | ||||
|
DIAL IN: |
866-880-4999 from within the U.S. | ||||
| 702-495-1913 from outside the U.S. | |||||
| Enter conference identification number 74214482 |
The live call also will be available at http://novabay.com/investors/events. A replay of the call will be available beginning two hours after its completion through 8:59 p.m. Eastern time December 3, 2015, by dialing 855-859-2056 from within the U.S. or 404-537-3406 from outside the U.S. and entering the conference identification number 74314482. The call will also be archived at http://novabay.com/investors/events.
About NovaBay Pharmaceuticals, Inc.: Going Beyond Antibiotics®
NovaBay
Pharmaceuticals is a biopharmaceutical company focusing on
commercializing and developing its non-antibiotic anti-infective
products to address the unmet therapeutic needs of the global, topical
anti-infective market with its two distinct product categories: the
NEUTROX™ Family of Products, including AVENOVA™
for the eye care market and NEUTROPHASE® for wound
care, and CELLERX® for the aesthetic
dermatology market, cleared by the FDA as a 510(k) medical device; and
its AGANOCIDE® compounds, led by AURICLOSENE™.
NovaBay has partnerships in the U.S. and around the world with PBE, Inc. (U.S.), IHT, Inc. (U.S.), Galderma (France), Virbac (France), China Pioneer Pharma (China and Southeast Asia), Shin Poong Pharmaceuticals (South Korea), Biopharm (North African and the Middle East), Sarmedic Ltd (Israel), Ophthalmic Instrument Company (New Zealand) and Alpha Pharma LLC (the Ukraine).
NovaBay has received FDA-clearance of its intelli-Case, a highly innovative, easy-to-use device for use with hydrogen peroxide disinfection solutions with soft and Rigid Gas Permeable (RGP) contact lenses.
Stay informed on NovaBay's progress:
Download
our Mobile InvestorApp from the Apple
Store or Google
Play
Like us on Facebook
Follow
us on Twitter
Connect
with NovaBay on LinkedIn
Join
us on Google+
Visit
NovaBay's
Website
